Our previous study reported that pan-HDAC inhibitor valproic acid (VPA) has a protective effect in the HFD-induced hypertension through inhibition of angiotensinogen expression in the kidney (Choi et al. 2017). This evidence concerns the gene AGT and hypertensive disorder.